Search the Newsreel

Applied Materials Inc. stock outperforms competitors on strong trading day

Shares of Applied Materials Inc. (AMAT) rose 5.55% to $535.31 on Monday, outperforming the broader market which saw declines in the S&P 500 Index and Dow Jones Industrial Average. This increase snapped a two-day losing streak for the stock.

REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron

Levi & Korsinsky, LLP is alerting investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about a pending securities class action. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which led to a significant stock price drop. Investors who purchased …

Diversified Marine Delivers Second Towboat To Vulcan Materials

Diversified Marine has delivered the M/V Edwin Rider, its second inland towboat for Vulcan Materials, built at their shipyard in Bourg, Louisiana. The vessel is 72 feet long and features a twin-screw propulsion system with two Mitsubishi S6R2 Tier 3 engines, totaling 1,600 horsepower, …

Why Medexus Pharmaceuticals Inc stock is sliding today

Modi Naturals wins Rs 140 crore ethanol order from OMCs

Why Platinum Group Metals Ltd stock is rising today

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript

Andean Precious Metals Stock: A Deliberate Bet on Higher Silver Prices

Altius Minerals Stock: Royalty Revenue Doubles to a Record C$30 Million

Altius Minerals (TSX:ALS): Is Valuation Getting Stretched?

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting

On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company's oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. …

2026 Stock-Split Watch: Is United Rentals on Deck?

When a stock reaches a certain price, some will worry that the buying pool becomes more limited, as retail investors may feel priced out. Often, when a stock hits $1,000 per share, that seems to be a psychological price level at which more shareholders …

PHAT Maintains Overweight Rating -- Price Target Lowered to $14

Barclays has maintained an "Overweight" rating for Phathom Pharmaceuticals (PHAT) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook despite the company being significantly undervalued according to GuruFocus's GF Value™. The company, which specializes in gastrointestinal treatments, faces financial health …

Ocular gains on EyePoint phase 3 wet AMD miss

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * Ocular Therapeutix (OCUL [https://seekingalpha.com/symbol/OCUL]) is up ~7% Monday following rival EyePoint's …

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign …

Why Arizona Metals Corp. stock is sliding today

Martin Marietta Materials (MLM) Extends Rocks and Gravel Theme

Weitz Investment Management, an investment management firm, released its second-quarter Q2 2026 investor letter for the "Large Cap Equity Fund". A copy of the letter can be downloaded here. The Large Cap Equity Fund's Institutional Class posted a return of 7.03% in Q2, trailing …

Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next

Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong Q2 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increased confidence in XDEMVY's commercial trajectory supports the company's near-term revenue, though risks related to …

NRX Pharmaceuticals earnings missed by $0.33, revenue fell short of estimates

NRX Pharmaceuticals (NASDAQ: NRXP) reported its second-quarter earnings, missing analyst estimates for both EPS and revenue. The company posted an EPS of $-0.440, significantly worse than the $-0.113 estimate, and revenue of $1.1M, falling short of the $1.75M consensus. Despite the miss, the stock …

Loss of China Rights for Jing Zhu Da Might Change The Case For Investing In Syndax (SNDX)

Host Hotels & Resorts stock holds at $22.90 as analysts reset price targets

Host Hotels & Resorts Inc. (US44107P1049) stock is currently trading at $22.90, with analysts setting price targets in the mid-$20s, implying potential upside. The lodging REIT has seen a significant year-to-date gain of approximately 29% as of August 14, 2026, despite recent short-term consolidation. …

Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral

Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from an "overweight" to a "neutral" rating, causing shares to fall by $10.59 to $4.16, near its 52-week low. Despite the downgrade, the consensus among analysts remains a "Moderate Buy" with a target price of $44.38. The company …

ZS Maintained by Wells Fargo -- Price Target Raised to $210

Wells Fargo has maintained an Overweight rating for Zscaler (ZS) and increased its price target from $180.00 to $210.00, indicating a bullish outlook due to the company's growth in the cybersecurity sector. Despite insider selling and profitability challenges, Zscaler is considered undervalued by GuruFocus's …

SUNB Initiated Coverage by Wells Fargo -- Rating Set to Overweig

Wells Fargo has initiated coverage on Sunbelt Rentals Holdings (SUNB) with an Overweight rating and a $96.00 price target. Despite strong profitability and growth metrics, the stock's current P/E ratio suggests it may be overvalued compared to its historical median. Insider selling and mixed …

Explore Rolls-Royce (LSE:RR.) as Long-Term Outlook Strengthens

Hyatt Hotels Corporation (H) Still Attractive Despite Recent Gains

Baron Capital, an investment management company, released its Q2 2026 letter for "Baron Partners Fund". A copy of the letter can be downloaded here. Baron Partners Fund reported a 16.61% (Institutional Shares) gain in Q2, outperforming both the Russell Midcap Growth Index (14.55%) and …

Worth Peripherals promoters acquire 2,039 equity shares in open market

Arizona Metals Corp. AMC Earnings Beat Estimates by 75.0%

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global sales for Xtandi® …

Robust Hotels Ltd: CRISIL ਵੱਲੋਂ ਰੇਟਿੰਗ 'BBB+/Stable' ਤੱਕ ਹੋਈ ਬੁਲੰਦ

EYPT Stock Slips As Insider Plans Share Sale

EyePoint Pharmaceuticals (EYPT) stock has dropped significantly following news of an insider's plan to sell securities, as indicated by an amended Form 144/A filing. While the company has a strong balance sheet with substantial cash reserves and a recent multi-week price climb, the insider …

Form 8K Eyepoint Pharmaceuticals Inc For: 17 August By Investing.com

This article reports on the filing of a Form 8K by Eyepoint Pharmaceuticals Inc. on August 17th. The brief piece includes the stock symbol EYPT, which is noted to be down 68.88%. No further details about the content of the Form 8K are provided.

Eyepoint Pharmaceuticals stock hits 52-week low at $4.06 By Investing.com

Eyepoint Pharmaceuticals Inc. (EYPT) stock recently hit a 52-week low of $4.06, despite a 33% increase over the past year. Analysts maintain a bullish outlook with an average price target suggesting a 58% upside. The company recently announced stockholder approval for an increase in …

EYPT Maintains Buy Rating by Chardan Capital -- Price Target Set at $65

Chardan Capital maintained its Buy rating for EyePoint Pharmaceuticals (EYPT) with a price target of $65.00, despite the stock being significantly overvalued according to GuruFocus's GF Value™ of $0.36 versus its current price of $14.76. The company also received a low GF Score™ of …

Enterprise value to revenue forward of Hindcon Chemicals Ltd. – NSE:HINDCON

Markets are pricing in Goldilocks. Deutsche Bank asks what could go wrong

Investing.com -- Deutsche Bank told clients in a note Monday that current market pricing rests on an optimistic set of assumptions that are unlikely to hold together, warning that the balance leaves almost no margin for error. Macro strategist Henry Allen said risk assets …